Cargando...

非小细胞肺癌T790M基因突变研究进展

Patients with advanced non-small cell lung cancer (NSCLC) carrying epidermal growth factor receptor (EGFR) activating mutations benefit from EGFR-tyrosine kinase inhibitor (TKI) treatment, however, most of TKI-treated patients eventually suffer drug resistant after 10-month treatments. Previous stud...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Zhongguo Fei Ai Za Zhi
Formato: Artigo
Idioma:Inglês
Publicado: 中国肺癌杂志编辑部 2013
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6000573/
https://ncbi.nlm.nih.gov/pubmed/23769347
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.08
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!